Evidence map›Paper›PMID 39707489›Full record

ArticleInfectious diseases of poverty2024

Assessment of compliance and therapeutic efficacy of albendazole treatment in Chinese patients with echinococcosis.

Min Qin, Guobing Yang, Jun Yan, Liying Wang, Yu Feng, Dong Wang, Qian Wang, Yanyan Hou, Jiangshan Zhao, Jiaxi Lei and 5 more

Abstract read
In one paragraph

Article in Infectious diseases of poverty, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Min Qin *National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Guobing Yang *Gansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Jun YanChinese Centre for Disease Control and Prevention, Beijing, China. yanjun@chinacdc.cn.
Liying WangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China. wangliyingcdc@163.com.ORCID http://orcid.org/0000-0002-2692-2770
Yu FengGansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Dong WangGansu Provincial Center for Disease Control and Prevention, Lanzhou, China.
Qian WangSichuan Provincial Center for Disease Control and Prevention, Chengdu, China.
Yanyan HouXinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Jiangshan ZhaoXinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi, China.
Jiaxi LeiNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Zhiyi WangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Mingzhe JiangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Chenghang YuNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Chinese Centre for Tropical Diseases Research); NHC Key Laboratory of Parasite and Vector Biology; WHO Collaborating Centre for Tropical Diseases, National Centre for International Research On Tropical Diseases, Shanghai, China.
Laurent GavotteEspace-Dev, UMR 228, Université de Montpellier, Montpellier, France.
Roger FrutosCentre de Cooperation International en Recherche Agronomique Pour Le Développement, UMR 17, Intertryp, Campus International de Baillarguet, Montpellier, France.

Funding

Gansu Provincial Health Industry Research Plan Project GSWSKY2017-19Natural Science Foundation of Gansu Province, China Grant No. 21JR11RA182NHC Key Laboratory of Echinococcosis Prevention and Control, China Grant No. 2024WZK1001
6 · The paper itself

Abstract

backgroundEchinococcosis is an infectious parasitic disease that is extremely harmful to human health. Albendazole is provided free of charge to patients requiring medication under the central government finance transfer payment scheme for echinococcosis control and prevention in China. Our aim is to monitor the state of patient medication and its therapeutic impact, which will help improve medication compliance and the therapeutic effect.

methodsRandom cluster sampling was used to select 10 echinococcosis-endemic counties in China, and all albendazole-treated patients in these counties were investigated. The chi-square and Kruskal-Wallis tests were used to compare two or more rates or constituent ratios, and multiple logistic regression analysis was used to identify the influencing factors. The records of patients were reviewed to obtain the initial diagnosis results as well as the most recent follow-up results and time, and efficacy was assessed.

resultsWe examined 899 patient files treated with albendazole in 10 endemic counties. Of the 582 evaluable files, 7.9% did not take albendazole, and 69.2% did not take albendazole regularly. Only 22.9% took albendazole regularly. Of the 536 patients who took albendazole, 242 exhibited adverse reactions. Patients who were Tibetan, herdsmen, received no formal education, used emulsion, and exhibited adverse reactions demonstrated poor compliance. A total of 174 patients with cystic echinococcosis received their most recent imaging follow-up results within one year of the investigation date. Among them, 9 patients met the criteria for cure, accounting for 5.2%; 56 patients showed effectiveness, accounting for 32.2%; 105 patients were deemed ineffective, accounting for 59.8%; 5 patients experienced recurrence, accounting for 2.9%.

conclusionsAlbendazole medication compliance in patients with echinococcosis is not ideal. We must prioritize health education and promotion for Tibetans, herdsmen, and those without formal education. Patients who adhered to their medication regimen achieved higher rates of cure and effectiveness. To improve medication compliance and efficacy, it is particularly important to improve communication and medication guidance for patients receiving emulsions and those with adverse reactions after taking albendazole. Simultaneously strengthen patients' attention to follow-up and re-examination.

Indexed as

AlbendazoleDrug MonitoringEchinococcosisAdolescentAdultAgedAnthelminticsChildChinaEast Asian PeopleFemaleHumansMaleMiddle AgedTreatment OutcomeYoung AdultAlbendazoleAnthelminticsAlbendazoleEchinococcosisMedication complianceTherapeutic effectTherapy

Identifiers

PMID39707489
PMCPMC11662814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.